Year-end Sale % OFF 
Abstract
We retrospectively analyzed the clinical records of 510 consecutive patients with diagnosis of low-intermediate risk of PCa, according to NCCN risk group and ASTRO-EAU- EORTC guidelines treated from Sept 1999 to Dec 2016 with I 125 BT LDR as monotherapy, using a real time approach at our Institution. As the nadir PSA value is a time-dependent variable, a landmark analysis method was used, and this demonstrated that lower nadir values at 3 years (fixed time point) after BT translated into improved long-term biochemical outcomes.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
